Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: Comparison of Etest and three automated testing methods

Journal of Clinical Microbiology

Volumn 51, Issue 7, 2013, Pages 2077-2081

  Rybak, Michael J ^a,b   Vidaillac, Celine ^a,h   Sader, Helio S ^c   Rhomberg, Paul R ^c   Salimnia, Hossein ^b,d   Briski, Lawrence E ^e   Wanger, Audrey ^f   Jones, Ronald N ^c,g  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JMI LABORATORIES   (United States)

^d DETROIT MEDICAL CENTER   (United States)

^e ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; BROTH DILUTION; CONTROLLED STUDY; EPSILOMETER TEST; INTERMETHOD COMPARISON; LABORATORY AUTOMATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; COMPARATIVE STUDY; DRUG EFFECTS; EVALUATION STUDY; HUMAN; MICROBIAL SENSITIVITY TEST; PROCEDURES;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; AUTOMATION, LABORATORY; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN;

EID: 84879457380     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00448-13     Document Type: Article

References (36)

1. Styers D, Sheehan DJ, Hogan P, Sahm DF. 2006. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob. 5:2.
2. Pillar CM, Draghi DC, Sheehan DJ, Sahm DF. 2008. Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs. Diagn. Microbiol. Infect. Dis. 60:221-224.
3. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98.
4. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52: 3315-3320.
5. Lodise TP, Miller CD, Graves J, Evans A, Graffunder E, Helmecke M, Stellrecht K. 2008. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 62:1138-1141.
6. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Jr, Eliopoulos GM. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402.
7. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200.
8. Kullar R, Davis SL, Levine DP, Rybak MJ. 2011. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin. Infect. Dis. 52:975-981.
9. Neuner EA, Casabar E, Reichley R, McKinnon PS. 2010. Clinical, microbiologic, and genetic determinants of persistent methicillinresistant Staphylococcus aureus bacteremia. Diagn. Microbiol. Infect. Dis. 67:228-233.
10. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, Anderson TL, Roberts SA, Gao W, Christiansen KJ, Coombs GW, Johnson PD, Howden BP. 2011. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J. Infect. Dis. 204:340-347.
11. van Hal SJ, Lodise TP, Paterson DL. 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. 54: 755-771.
12. Moore MR, Perdreau-Remington F, Chambers HF. 2003. Vancomycin treatment failure associated with heterogeneous vancomycinintermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob. Agents Chemother. 47: 1262-1266.
13. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. 2009. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 199:619-624.
14. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK. 2006. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 50:3039-3047.
15. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PD, Morris AJ, Mayall BC, Grayson ML. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528.
16. Bae IG, Federspiel JJ, Miro JM, Woods CW, Park L, Rybak MJ, Rude TH, Bradley S, Bukovski S, de la Maria CG, Kanj SS, Korman TM, Marco F, Murdoch DR, Plesiat P, Rodriguez-Creixems M, Reinbott P, Steed L, Tattevin P, Tripodi MF, Newton KL, Corey GR, Fowler VG, Jr. 2009. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J. Infect. Dis. 200:1355-1366.
17. Medves J, Godfrey C, Turner C, Paterson M, Harrison M, MacKenzie L, Durando P. 2010. Systematic review of practice guideline dissemination and implementation strategies for healthcare teams and team-based practice. Int. J. Evid. Based Healthc. 8:79-89.
18. van Hal SJ, Paterson DL. 2011. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55:405-410.
19. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN. 2008. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J. Clin. Microbiol. 46:2950-2954.
20. Tenover FC, Moellering RC, Jr. 2007. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44:1208-1215.
21. Sader HS, Jones RN, Rossi KL, Rybak MJ. 2009. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine U. S. A. hospitals. J. Antimicrob. Chemother. 64:1024-1028.
22. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. 2011. Vancomycin: we can't get there from here. Clin. Infect. Dis. 52:969-974.
23. Lodise TP, Lomaestro B, Graves J, Drusano GL. 2008. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 52:1330-1336.
24. Mohr JF, Murray BE. 2007. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 44:1536-1542.
25. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, M JR, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52:285-292.
26. Lubin AS, Snydman DR, Ruthazer R, Bide P, Golan Y. 2011. Predicting high vancomycin minimum inhibitory concentration in methicillinresistant Staphylococcus aureus bloodstream infections. Clin. Infect. Dis. 52:997-1002.
27. Deresinski S. 2012. Methicillin-resistant Staphylococcus aureus and vancomycin: minimum inhibitory concentration matters. Clin. Infect. Dis. 54:772-774.
28. Swenson JM, Anderson KF, Lonsway DR, Thompson A, McAllister SK, Limbago BM, Carey RB, Tenover FC, Patel JB. 2009. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J. Clin. Microbiol. 47: 2013-2017.
29. Kruzel MC, Lewis CT, Welsh KJ, Lewis EM, Dundas NE, Mohr JF, Armitige LY, Wanger A. 2011. Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 49:2272-2273.
30. Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, Wong-Beringer A. 2008. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents. 32:378-385.
31. Bland CM, Porr WH, Davis KA, Mansell KB. 2010. Vancomycin MIC susceptibility testing of methicillin-susceptible and methicillin-resistant Staphylococcus aureus isolates: a comparison between Etest(R) and an automated testing method. South Med. J. 103:1124-1128.
32. Liu Y, Cao B, Gu L, Liu K, Feng Z. 2012. Successful control of vancomycin-resistant Enterococcus faecium nosocomial outbreak in a teaching hospital in China. Am. J. Infect. Control. 40:568-571.
33. Sader HS, Fey PD, Limaye AP, Madinger N, Pankey G, Rahal J, Rybak MJ, Snydman DR, Steed LL, Waites K, Jones RN. 2009. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob. Agents Chemother. 53:4127-4132.
34. Clincial and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. CLSI M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
35. Baker CN, Tenover FC. 1996. Evaluation of Alamar colorimetric broth microdilution susceptibility testing method for staphylococci and enterococci. J. Clin. Microbiol. 34:2654-2659.
36. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, M JR, Talan DA, Chambers HF, Infectious Diseases Society of America. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18-e55. doi:10.1093/cid/ciq146.